[1]牛文慧 王蕾.犬尿酸-G蛋白偶联受体35信号通路在代谢性心血管疾病中的研究进展[J].心血管病学进展,2026,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2026.01.001]
　NIU Wenhui,WANG Lei.Kynurenic Acid-G Protein-Coupled Receptor 35 Signaling Pathway in Metabolic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2026,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2026.01.001]
点击复制

犬尿酸-G蛋白偶联受体35信号通路在代谢性心血管疾病中的研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2026年1期
页码:
1
栏目:
综述
出版日期:
2026-01-25

文章信息/Info

Title:
Kynurenic Acid-G Protein-Coupled Receptor 35 Signaling Pathway in Metabolic Cardiovascular Diseases
作者:
牛文慧 王蕾
(首都医科大学公共卫生学院营养与食品卫生系,环境与衰老北京市重点实验室,北京 100069)
Author(s):
NIU Wenhui; WANG Lei
(Department of Nutrition and Food Hygiene,School of Public Health,Capital Medical University,Beijing Key Laboratory of Environmental and Aging,Beijing 100069,China)
关键词:
犬尿酸; G蛋白偶联受体35; 心血管疾病; 代谢性心血管疾病
Keywords:
Kynurenic acid; G protein-coupled receptor 35; Cardiovascular diseases; Metabolic cardiovascular diseases
DOI:
10.16806/j.cnki.issn.1004-3934.2026.01.001
摘要:
代谢性心血管疾病是全球重大公共卫生问题，发病率与死亡率持续攀升，其核心发病机制与代谢紊乱密切相关。犬尿酸是色氨酸代谢的终末产物，在多种具有代谢性心血管疾病危险因素的患者体内显著降低且参与疾病进展。近年研究发现，犬尿酸激活G蛋白偶联受体35发挥抗炎、改善代谢及调控心血管功能等作用。现系统综述犬尿酸-G蛋白偶联受体35信号通路在代谢性心血管疾病中的最新研究进展，以期为代谢性心血管疾病的诊疗和靶向干预策略提供理论依据和新靶点。
Abstract:
Metabolic cardiovascular diseases are a major global public health issue,with their incidence and mortality continuing to rise. The core pathogenic mechanisms are closely associated with metabolic disturbances. Kynurenic acid,a terminal metabolite of tryptophan metabolism,is significantly reduced in patients with various metabolic cardiovascular disease risk factors and plays a role in disease progression. Recent studies have shown that kynurenic acid activates G protein-coupled receptor 35 (GPR35),thereby exerting anti-inflammatory effects,improving metabolism,and regulating cardiovascular function. This review systematically summarizes recent advances in the kynurenic acid-GPR35 signaling pathway in metabolic cardiovascular diseases,aiming to provide a theoretical basis and novel targets for their diagnosis,treatment,and targeted interventions

参考文献/References:

[1] Townsend N,Kazakiewicz D,Lucy Wright F,et al. Epidemiology of cardiovascular disease in Europe[J]. Nature Reviews Cardiology,2022,19(2):133-143.

[2] Akyea RK,Ntaios G,Doehner W. Obesity,metabolic health and clinical outcomes after incident cardiovascular disease:a nationwide population-based cohort study[J]. J Cachexia Sarcopenia Muscle,2023,14(6):2653-2662.

[3] Zhao D,Liu J,Wang M,et al. Epidemiology of cardiovascular disease in China:current features and implications[J]. Nature Reviews Cardiology,2019,16(4):203-212.

[4] Fu J,Deng Y,Ma Y,et al. National and provincial-level prevalence and risk factors of carotid atherosclerosis in Chinese adults[J]. JAMA Netw Open,2024,7(1):e2351225.

[5] Ferrannini G,de Bacquer D,de Backer G,et al. Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease—A persistent challenge in need of substantial improvement:a report from ESC EORP EUROASPIRE V[J]. Diabetes Care,2020,43(4):726-733.

[6] Chong B,Jayabaskaran J,Jauhari SM,et al. Global burden of cardiovascular diseases:projections from 2025 to 2050[J]. Eur J Prev Cardiol,2025,32(11):1001-1015.

[7] Liebig J. Ueber Kynurens?ure[J]. Justus Liebigs Annalen der Chemie,1853,86(1):125-126.

[8] Turska M,Paluszkiewicz P,Turski WA,et al. A review of the health benefits of food enriched with kynurenic acid[J]. Nutrients,2022,14(19):4182.

[9] Zhu H,Yang X,Zhao Y. Recent advances in current uptake situation,metabolic and nutritional characteristics,health,and safety of dietary tryptophan[J]. J Agricu Food Chem,2024,72(13):6787-6802.

[10] Xue C,Li G,Zheng Q,et al. Tryptophan metabolism in health and disease[J]. Cell Metab,2023,35(8):1304-1326.

[11] Agus A,Planchais J,Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease[J]. Cell Host Microbe,2018,23(6):716-724.

[12] Sadik A,Somarribas Patterson LF,?ztürk S,et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression[J]. Cell,2020,182(5):1252-1270.e1234.

[13] Li J,Zhang Y,Yang S,et al. The beneficial effects of edible kynurenic acid from marine horseshoe crab (Tachypleus tridentatus) on obesity,hyperlipidemia,and gut microbiota in high-fat diet-fed mice[J]. Oxid Med Cell Longev,2021,2021:8874503.

[14] Agudelo LZ,Ferreira DMS,Cervenka I,et al. Kynurenic acid and Gpr35 regulate adipose tissue energy homeostasis and inflammation[J]. Cell Metab,2018,27(2):378-392.e375.

[15] Gao Y,Guo X,Zhou Y,et al. Kynurenic acid inhibits macrophage pyroptosis by suppressing ROS production via activation of the NRF2 pathway[J]. Mol Med Rep,2023,28(5):211.

[16] Balla Z,Kormányos ES,Kui B,et al. Kynurenic acid and its analogue SZR-72 ameliorate the severity of experimental acute necrotizing pancreatitis[J]. Front Immunol,2021,12:702764.

[17] Stone TW,Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway[J]. Trends Pharmacological Sci,2023,44(7):442-456.

[18] Knapskog AB,Aksnes M,Edwin TH,et al. Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer’s disease[J]. Alzheimers Dement,2023,19(12):5573-5582.

[19] Zheng H,Teague TK,Yeh FC,et al. C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder[J]. Brain Behav Immun,2022,105:180-189.

[20] Bratek-Gerej E,Ziembowicz A,Godlewski J,et al. The mechanism of the neuroprotective effect of kynurenic acid in the experimental model of neonatal hypoxia-ischemia:the link to oxidative stress[J]. Antioxidants (Basel),2021,10(11):1775.

[21] Ramírez Ortega D,Ugalde Mu?iz PE,Blanco Ayala T,et al. On the antioxidant properties of L-kynurenine:an efficient ros scavenger and enhancer of rat brain antioxidant defense[J]. Antioxidants (Basel),2021,11(1):31.

[22] Li Y,Zhang L,Wu D,et al. Kynurenic acid,a small foodborne molecule with the potential to affect human health[J]. J Agric Food Chem,2025,73(15):8729-8739.

[23] Quon T,Lin LC,Ganguly A,et al. Therapeutic opportunities and challenges in targeting the orphan G protein-coupled receptor GPR35[J]. ACS Pharmacol Transl Sci,2020,3(5):801-812.

[24] Takkar S,Sharma G,Kaushal JB,et al. From orphan to oncogene:the role of GPR35 in cancer and immune modulation[J]. Cytokine Growth Factor Rev,2024,77:56-66.

[25] Cheng L,Wu H,Cai X,et al. A Gpr35-tuned gut microbe-brain metabolic axis regulates depressive-like behavior[J]. Cell Host Microbe,2024,32(2):227-243.e6.

[26] Sun T,Xie R,He H,et al. Kynurenic acid ameliorates NLRP3 inflammasome activation by blocking calcium mobilization via GPR35[J]. Front Immunol,2022,13:1019365.

[27] Wu X,Chen S,Yan Q,et al. Gpr35 shapes gut microbial ecology to modulate hepatic steatosis[J]. Pharmacol Res,2023,189:106690.

[28] Wang H,Li J,Wang Z,et al. Perivascular brown adipocytes-derived kynurenic acid relaxes blood vessel via endothelium PI3K-Akt-eNOS pathway[J]. Biomed Pharmacother,2022,150:113040.

[29] B?dzyńska B,Zakrocka I,Turski WA,et al. Kynurenic acid selectively reduces heart rate in spontaneously hypertensive rats[J]. Naunyn Schmiedebergs Arch Pharmacol,2020,393(4):673-679.

[30] Zhen D,Ding L,Wang B,et al. Oral administration of kynurenic acid delays the onset of type 2 diabetes in Goto-Kakizaki rats[J]. Heliyon,2023,9(7):e17733.

[31] Jung TW,Park J,Sun JL,et al. Administration of kynurenic acid reduces hyperlipidemia-induced inflammation and insulin resistance in skeletal muscle and adipocytes[J]. Mol Cell Endocrinol,2020,518:110928.

[32] Wei X,Yin F,Wu M,et al. G protein-coupled receptor 35 attenuates nonalcoholic steatohepatitis by reprogramming cholesterol homeostasis in hepatocytes[J]. Acta Pharm Sin B,2023,13(3):1128-1144.

[33] Lin LC,Quon T,Engberg S,et al. G protein-coupled receptor GPR35 suppresses lipid accumulation in hepatocytes[J]. ACS Pharmacol Transl Sci,2021,4(6):1835-1848.

[34] Min KD,Asakura M,Liao Y,et al. Identification of genes related to heart failure using global gene expression profiling of human failing myocardium[J]. Biochem Biophys Res Commun,2010,393(1):55-60.

[35] Divorty N,Milligan G,Graham D,et al. The orphan receptor GPR35 contributes to angiotensin ii-induced hypertension and cardiac dysfunction in mice[J]. Am J Hypertens,2018,31(9):1049-1058.

[36] Li H,Nguyen H,Meda Venkata SP,et al. Novel role of GPR35 (G-protein-coupled receptor 35) in the regulation of endothelial cell function and blood pressure[J]. Hypertension,2021,78(3):816-830.

[37] Ronkainen VP,Tuomainen T,Huusko J,et al. Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling[J]. Cardiovasc Res,2014,101(1):69-77.

[38] Chen K,He L,Li Y,et al. Inhibition of GPR35 preserves mitochondrial function after myocardial infarction by targeting calpain 1/2[J]. J Cardiovasc Pharmacol,2020,75(6):556-563.

[39] Wood N,Straw S,Cheng CW,et al. Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction[J]. Eur J Heart Fail,2024,26(4):925-935.

[40] Bakhta O,Pascaud A,Dieu X,et al. Tryptophane-kynurenine pathway in the remote ischemic conditioning mechanism[J]. Basic Res Cardiol,2020,115(2):13.

[41] Wyant GA,Yu W,Doulamis IP,et al. Mitochondrial remodeling and ischemic protection by G protein–coupled receptor 35 agonists[J]. Science,2022,377(6606):621-629.

[42] Bigelman E,Pasmanik-Chor M,Dassa B,et al. Kynurenic acid,a key L-tryptophan-derived metabolite,protects the heart from an ischemic damage[J]. PLoS One,2023,18(8):e0275550.

[43] Tian X,Kan H,Yang L,et al. Investigating the role of TRPV4 and GPR35 interaction in endothelial dysfunction in aging mice[J]. Aging Cell,2024(5):e14469.

[44] Baumgartner R,Berg M,Matic L,et al. Evidence that a deviation in the kynurenine pathway aggravates atherosclerotic disease in humans[J]. J Intern Med,2021,289(1):53-68.

[45] Lee T,Park HS,Jeong JH,et al. Kynurenic acid attenuates pro-inflammatory reactions in lipopolysaccharide-stimulated endothelial cells through the PPARδ/HO-1-dependent pathway[J]. Mol Cell Endocrinol,2019,495:110510.

[46] Baumgartner R,Casagrande FB,Mikkelsen RB,et al. Disruption of GPR35 signaling in bone marrow-derived cells does not influence vascular inflammation and atherosclerosis in hyperlipidemic mice[J]. Metabolites,2021,11(7):411.

相似文献/References:

[1]宋志平 杨永健.GPR 35在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
　SONG Zhiping,YANG Yongjian.The Current Progress of GPR 35 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
[2]国涛 蔺雪峰 李阳 罗星.犬尿酸抑制M1型巨噬细胞极化改善盐敏感性高血压的作用与机制研究[J].心血管病学进展,2026,(2):186.[doi:10.16806/j.cnki.issn.1004-3934.2026.02.017]
　GUO Tao,LIN Xuefeng,LI Yang,et al.The effect and Mechanism of Kynurenic Acid on Salt-Sensitive Hypertension by Inhibiting the M1 Polarization of Macrophages[J].Advances in Cardiovascular Diseases,2026,(1):186.[doi:10.16806/j.cnki.issn.1004-3934.2026.02.017]

更新日期/Last Update: 2026-05-14